[Editors note: 7 Biotech Stocks to Buy and Hold in 2020 was previously published in December 2019. It has since been updated to include the most relevant information available.]

If it were not for the surge in stock prices in the fourth quarter, biotechnology stocks would have ended the year in double-digit losses. Instead, they had a banner end of the year and now are suffering or succeeding based on the coronavirus and broad market pressures.

At a macroeconomic level, markets now believe the government regulators will not scrutinize drug pricing. The government is starting to realize that high healthcare costs are not due solely to rising drug prices. So, biotech companies that raise prices to offset higher research and development costs may do so in 2020.

Mega mergers in 2019, like AbbVie (NYSE:ABBV) buying Allergan (NYSE:AGN), signaled the undervaluation in the sector. In 2020, price-to-earnings valuations may expand to correct the market discount.

There are seven biotechnology stocks in 2020 that investors should hone in on. Get ready to pop these in your portfolio.

Source: Pavel Kapysh / Shutterstock.com

Biogen (NASDAQ:BIIB) rose from $220 to $300 in October when the company said it would resume filing for approval to bring its Alzheimers therapy drug to market. Then on Dec. 6, the company presented Phase 3 results for Aducanumab.

Over an 18-month period, it enrolled 3,285 patients over the two studies. The results showed that with a high dose over a long period of time, there was a meaningful slowing of decline in Alzheimers patients. And so, if the drug passes regulatory review, BIIB stock will live up to its hype.

The Aducanumab data showed mixed results. Although a higher dosage benefited patients, the side effects on the higher dosage are not clear.

Biogen reported steady revenue growth in the third quarter. Revenue grew 5% to $3.6 billion as earnings per share grew 17% to $8.39 (on a GAAP basis). Its multiple sclerosis drug portfolio is resilient. But Biogen is focused on addressing the intellectual property challenge with Tecfidera, a drug that treats relapsing forms of MS. This is offset by the launch of Vumerity, a drug also used to treat people with relapsing forms of MS.

Biogen reported revenue for Spinraza growing in the double-digits year-over-year and quarter-over-quarter. This drug treats patients with spinal muscular atrophy (SMA). Since Spinraza has a well-characterized safety profile, Biogen will run further studies to evaluate the benefits of higher doses to achieve greater efficacy.

Analysts who offer a price target on BIIB stock have an average of a $306.75 price target.

Source: Michael Vi / Shutterstock.com

Amgen (NASDAQ:AMGN) trades with analyst price targets that average $248. But at a trailing P/E of 18.6 times, the companys Otezla acquisition from Celgene (NASDAQ:CELG) is accretive to full-year results.

Last year Amgen announced a collaboration with BeiGene (NASDAQ:BGNE). Forming collaborations are in Amgens growth strategy. Since 2011, it grew by expanding to 100 countries, including China and other emerging markets. BeiGene, which represents a strategic investment in China, offers strong oncology expertise. It also has good commercial and clinical capabilities.

In 2020 and beyond, the Amgen-BeiGene collaboration may accelerate the commercialization of Amgens approved oncology products in the region. It paid $2.7 billion for a 20.5% equity stake, which was a 36% premium to BeiGenes 30-day average share price.

In Q3, Amgen reported EPS of $3.66. Revenue declined 2.9% to $5.7 billion. Despite a global sales decline, Amgen reported double-digit sales for a multitude of drugs. If generic competition lessens in 2020 and drug pricing improves, Amgen stock could continue trending higher.

Source: Casimiro PT / Shutterstock.com

Gilead Sciences (NASDAQ:GILD) surged early as a coronavirus darling before getting sucked back down into range by the prevailing market forces. And as investors wait for the stock to build an uptrend, they may collect a dividend that yields around 4%.

The U.S. approved Gileads Descovy for PrEP (pre-exposure prophylaxis). This drug is indicated to reduce the risk of sexually acquired HIV-1. Filgotinib was validated in the European Union and the company submitted a new drug application in Japan. Filgotinib is a JAK1 inhibitor that treats rheumatoid arthritis. If approved, it will compete with AbbVies (NYSE:ABBV) Humira.

Setting aside Gileads viability as a coronavirus vaccine leader, investors should consider Gilead for 2020 because of its strong cash flow generation. It produced $2.6 billion in cash from operations in the third quarter and now has $25.1 billion in cash and investments.

That healthy cash flow allowed the company to easily spend on R&D. It paid $5.5 billion for global research collaboration activities and it also invested in Galapagos (NASDAQ:GLPG). Galapagos gives Gilead access to many compounds, including six molecules that are in clinical trials. For example, Gilead gains rights to a Phase 3 candidate that treats idiopathic pulmonary fibrosis. GLPG1972 is a Phase 2b candidate that treats osteoarthritis.

Gilead could grow its revenue beyond the 12.7% rate. If its purchase of Kite Pharmaceuticals yields new products brought to market, the stock is set to blast off in late 2020 and beyond.

Source: Shutterstock

Regeneron (NASDAQ:REGN), which is getting better known for its blockbuster drug Dupixent, broke out of a downtrend late last year and hasnt stopped growing.

The company reported an EPS of $6.67 as revenue soared 23.1% year-over-year to $2.1 billion. Markets incorrectly worried over generic pressure on Eylea, which treats advanced wet age-related macular degeneration. Eylea sales grew 14% to $1.9 billion.

Dupixent has a growing addressable market. As it gains approvals worldwide, sales might even accelerate. In 2020, Regeneron will continue investing in researching activities for the drug to have additional indications.

For example, late this year it will have data in combination with Aimmunes (NASDAQ:AIMT) AR101 for treating peanut allergies. It will also have a data readout for its interleukin-33 (IL-33) antibody called Regeneron 3500 for treating atopic dermatitis and COPD (chronic obstructive pulmonary disease).

Regeneron continues to develop drugs in the oncology market. It launched Libtayo, an anti-PD-1 therapy that treats cutaneous squamous cell carcinoma. It also has new data from Libtayo in treating lung cancer.

At a P/E near 20 times, Regeneron still has plenty of upside potential. Even if the companys revenue were to slow to the 4% range in the next five years, the stock is still worth around $526.

Source: Shutterstock

Crispr Therapeutics (NASDAQ:CRSP), which is based in Switzerland, almost doubled in 2019. So after that performance, why should investors expect any more upside in 2020?

CRSP reported encouraging results for a potential immune-evasive cell replacement therapy for diabetes. From its press release, it said: The data demonstrate that the CyT49 pluripotent stem cell line, which has been shown to be amenable to efficient scaling and differentiation, can be successfully edited with CRISPR.

The results are further proof that regenerative medicine and gene editing may lead to cures in various diseases. Crispr is currently focusing on chronic diseases like diabetes.

Optimism for CRSP stock is so strong that a 4.3 million stock offering at $64.50 barely hurt the stock. The stock sale will add $274.1 million of cash, which Crispr may use to fund its ongoing clinical studies in sickle cell disease and beta-thalassemia.

Digging into the details, Crispr said that it successfully treated its first patient in the CLIMB SCD-121 study. The neutrophil engraftment had 46.6% hemoglobin F four months later. That suggests a curative response. Since the study is ongoing, the company will continue to inform investors of the safety profile of the treatment and its efficacy.

Crispr is ushering in an innovative form of therapy through gene editing. And markets like what the future holds.

Source: Shutterstock

Editas Medicine (NASDAQ:EDIT) has negligible revenue and is losing money, but its collaboration with Celgene gives it the resources in advancing its pipeline.

Editas reported a $70 million payment from its Celgene collaboration. This payment is in recognition of the work it did so far. It also includes contributions it will make to the collaboration. Its first patient will receive a doss of EDIT-101 by early 2020. This medicine treats subjects suffering from LCA10 or Leber congenital amaurosis. In Q3, Editas presented data for its USH2A study. It produced up to 60% corrected gene expression.

Looking ahead, additional collaborations with Celgene could give EDIT stock a lift. On its conference call, the company said:

All of that work is rolled into the new collaboration with Celgene. As you can imagine, as a leader and we believe the leader in T cell medicines for oncology including arguably the best CD19 and the best BCMA CAR-T programs that have a strong interest in maintaining their leadership position and gene editing is certainly an important part of what are likely to be the next generation of T cell medicines for oncology.

Editas collaboration with Celgene continues to progress nicely. Wall Street, which has a $42.50 price target, is also optimistic that the company will reward investors in 2020.

Source: Shutterstock

Innoviva (NASDAQ:INVA) has been trading sidewas all year until the recent mass-sell-off.

Last year, Innoviva booked $69.2 million in gross royalty revenues from GlaxoSmithKline(NYSE:GSK). This included royalties of $46.4 million connected to sales of Relvar/Breo Ellipta. This drug is a combination inhaled corticosteroid that treats patients with COPD (chronic obstructive pulmonary disease). Anoro Ellipta, which treats COPD and is taken once daily, brought in royalties of $11.6 million.

The company had $2.8 million in legal and related fees. Theravance Biopharma (NASDAQ:TBPH) initiated an arbitration. In the final decision, the Theravance Respiratory Company would reimburse those legal costs.

Global Relvar/Breo Ellipta sales fell 10% globally and by 32% in the U.S. Pricing discounts hurt revenue, and that revenue was partially offset by volume growth. Market share gains in various European markets and in Japan offset the overall revenue declines. Anoro Ellipta net sales grew 18% globally and were up 17% in the U.S. The negative impact of higher rebates was offset by higher sales volumes.

For 2020, Innoviva has a lower operating cost basis, helped by ending its Brisbane office lease. So, if the company reduces rebate offers and continues to grow its sales volume, revenue and profits may rebound.

As of this writing, Chris Lau held shares of INVA.

Here is the original post:
7 Biotech Stocks to Buy and Hold in 2020 - Investorplace.com

Recommendation and review posted by Bethany Smith

Several government organizations and private institutions are investing in the regenerative medicine industry, for research and development. New development is undertaken as per the rules and regulations standardized by organizations like Food and Drug Administration (FDA) in the USA, the European Medicines Agency (EMA) in Europe and other regional authorities.

Request a sample of this report @https://www.adroitmarketresearch.com/contacts/request-sample/52

From being able to identify and heal life threatening diseases, to their prevention, the health and medicine sector has witnessed a revolutionary development over the years, with regenerative medicine being a major innovation.

The average life expectancy of a human being has increased, thus giving rise to the geriatric population. That, coupled with the increasing number of neurodegenerative, orthopedic, oncological, genetic and chronic disorders, constitutes the major factors that are fuelling the growth of the regenerative medicine market size. It has provided a tremendous opportunity to manufacturers, to satisfy this demand of the market. They are collaborating with leading research specialists, labs, pharmaceutical and biotechnology companies, and investors, towards the invention of more regenerative medicines, like gene therapy, nanotechnology, and tissue engineering. The regenerative medicine industry is evolving as one of the most cost-effective and definitive healthcare solutions. Regenerative medicine product analysis shows cell therapy fetching the highest revenue in the forecast period followed by tissue engineering, gene therapy and small molecules and biologics.

Browse the complete report @https://www.adroitmarketresearch.com/industry-reports/regenerative-medicine-market

North America is expected to hold the highest regenerative medicine market share which invests in oncology and stem cell research. Presence of organizations such as National Cancer Institute, Alliance for Regenerative Medicine, National Institutes of Health and International Society for stem cell research supports the research and development of regenerative medicine which is accelerating the growth in this region. The Asia Pacific region is expected to witness the fastest growth during the forecast period, owing to the population growth in this region. Countries like China and Japan are introducing flexible regulations towards the clinical adoption of regenerative medicine techniques. The government is also actively participating in funding towards the infrastructure required for the research and development. Thus, boosting the global regenerative medicine market further.

What to expect from the upcoming report on Global Regenerative Medicine Market:

Growth projections of the global regenerative medicine market during the forecast period (2018-2025).

-Areas of growth and concern in the field of regenerative medicine.

Economic factors likely to influence the market.

Trends, drivers, opportunities, restraints, and challenges in the development and use of regenerative medicine.

The involvement of government and other private organizations that are elevating the research and development of regenerative medicine.

Analysis of the regional demographics affecting the market.

Information about the competitors in the market, and the initiatives taken by them to improve this market.

Pre-book the research study on Regenerative Medicine and Get Flat 10% Discount @https://www.adroitmarketresearch.com/researchreport/purchase/52

About Us:

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Info:

Ryan Johnson

Adroit Market Research

3131 McKinney Ave Ste 600,

Dallas, Texas 75204, U.S.A

Phone No: +19723628199

Email:[emailprotected]

Read this article:
Regenerative Medicine Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis, And Key Country...

Recommendation and review posted by Bethany Smith

The Alcor Life Extension Foundation is the world leader incryonics,cryonicsresearch, andcryonics technology.Cryonicsis the practice of using ultra-cold temperature to preserve a human body with the intent of restoring good health when thetechnologybecomes available to do.

The Cryonics Technology Market to raise in terms of revenues and CAGR values during the forecast period 2020-2027

The report, titled Cryonics Technology Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

Request for Sample Copy @ https://www.theresearchcorporation.com/request-sample.php?id=18983

Top Key Players of Cryonics Technology Market: Praxair, Cellulis, Cryologics, Cryotherm, KrioRus, VWR, Thermo Fisher Scientific, Custom Biogenic Systems, Oregon Cryonics, Alcor Life Extension Foundation, Osiris Cryonics, Sigma-Aldrich

The Research Corporation report focuses on the Cryonics Technology Market provides the analysis report includes the drivers and restraints of the market space along with data regarding the innovative progress in the field. Moreover, it explains the essential constituents to gain stability and maintain a persistent evolution in this industry. It elaborates on the variety of techniques that are implemented by the present key players and sheds light upon the amendments required to suit the developments in the market.

Get Discount on This Report @ https://www.theresearchcorporation.com/ask-for-discount.php?id=18983

The region segments of Cryonics Technology Market are: United States, Europe, China, Japan, Southeast Asia, India, Central & South America.

By Market Product: Slow freezing, Vitrification, Ultra-rapidBy Application: Animal husbandry, Fishery science, Medical science, Preservation of microbiology culture, Conserving plant biodiversity

Table of Content:

Enquiry before buying@ https://www.theresearchcorporation.com/enquiry-before-buying.php?id=18983

About Us

The Research Corporation symbolizes current market trends in the global industry. Our mastery in the field of market insights and analysis makes our company an ideal platform for clients seeking pioneering research in the lucrative global market fields.

At The Research Corporation we work diligently on delivering prudent market insights with sound market intelligence; with that we take pride in delivering comprehensive industry insights based on the market, market competitors, products and global customers. Through our erudite market approach, The Research Corporation has become synonymous to delivering best product service.

Contact:

The Research Corporation

William K (Sales Manager)

1632 1st Avenue, New York, NY 10028, USA

+1 929 299 7373

sales@theresearchcorporation.com

Link:
Huge Demand of Cryonics Technology Market 2020 Predictable to Witness Sustainable Evolution Over 2024 Including Leading Vendors- Praxair, Cellulis,...

Recommendation and review posted by Bethany Smith

A detailed research study on the Cryonics Technology Market was recently published by DataIntelo. The report puts together a concise analysis of the growth factors influencing the current business scenario across various regions. Significant information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present an ensemble prediction. Additionally, this report encompasses an accurate competitive analysis of major market players and their strategies during the projection timeline.

The latest report on the Cryonics Technology Market consists of an analysis of this industry and its segments. As per the report, the market is estimated to gain significant returns and register substantial y-o-y growth during the forecast period.

Request a Sample Report of Cryonics Technology Market at: https://dataintelo.com/request-sample/?reportId=92114

According to the report, the study offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections. The report documents factors such as drivers, restraints, and opportunities that impacts the remuneration of this market.

An Outline of the Major Key Points of the Cryonics Technology Market Report:

Ask for Discount on Cryonics Technology Market Report at: https://dataintelo.com/ask-for-discount/?reportId=92114

The Geographical Landscape of the Market Include:

Buy Your Exclusive PDF Copy Now @ https://dataintelo.com/checkout/?reportId=92114

Some of the Major Highlights of TOC Covers:Chapter 1: Executive Summary

Chapter 2: Methodology & Scope

Chapter 3: Market Insights

Chapter 4: Company Profiles

For More Information on this report, Request Inquiry At: https://dataintelo.com/enquiry-before-buying/?reportId=92114

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

Original post:
Cryonics Technology Market Comprehensive Study With Key Trends, Major Drivers And Challenges 2020-2026 - News Times

Recommendation and review posted by Bethany Smith

The study on Global Cryonics Technology Market, offers deep insights about the Cryonics Technology Market covering all the crucial aspects of the market. Moreover, the report provides historical information with future forecast over the forecast period. Some of the important aspects analyzed in the report includes market share, production, key regions, revenue rate as well as key players. This Cryonics Technology report also provides the readers with detailed figures at which the Cryonics Technology Market was valued in the historical year and its expected growth in upcoming years. Besides, analysis also forecasts the CAGR at which the Cryonics Technology is expected to mount and major factors driving markets growth.

Top Players Included In This Report:

The major players covered in Cryonics Technology are:PraxairCustom Biogenic SystemsCryothermCellulisThermo Fisher ScientificCryologicsAlcor Life Extension FoundationVWRKrioRusOregon CryonicsOsiris CryonicsSigma-AldrichSouthern Cryonics

Get A PDF Sample Of This Report @ https://www.orbisresearch.com/contacts/request-sample/4303566

The Global Cryonics Technology Market is a highly competitive market. It has some players who have been in the business for quite some time. Subsequently there are many startups coming up to seize the huge opportunity this market offers. Some players have a presence only in a particular geography. In addition, the projections offered in this report have been derived with the help of proven research assumptions as well as methodologies. By doing so, the Cryonics Technology research study offers collection of information and analysis for each facet of the Cryonics Technology Market such as technology, regional markets, applications, and types. Likewise, the Cryonics Technology Market report offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the Global Cryonics Technology Market.

In addition to this, the report has been designed through the complete surveys, primary research interviews, as well as observations, and secondary research. Likewise, the Global Cryonics Technology Market report also features a comprehensive quantitative and qualitative evaluation by analyzing information collected from market experts and industry participants in the major points of the market value chain. This study offers a separate analysis of the major trends in the existing market, orders and regulations, micro & macroeconomic indicators is also comprised in this report. By doing so, the study estimated the attractiveness of every major segment during the prediction period.

Access The Complete Report @ https://www.orbisresearch.com/reports/index/global-cryonics-technology-market-2020-by-company-regions-type-and-application-forecast-to-2025

Types Covered In This Report:

By Type, Cryonics Technology market has been segmented into:Slow freezingVitrificationUltra-rapid

Applications Covered In This Report:

By Application, Cryonics Technology has been segmented into:Animal husbandryFishery scienceMedical sciencePreservation of microbiology cultureConserving plant biodiversity

The Cryonics Technology Market has its impact all over the globe. On Global level Cryonics Technology industry is segmented on the basis of product type, applications, and regions. It also focusses on market dynamics, Cryonics Technology growth drivers, developing market segments and the market growth curve is offered based on past, present and future market data. The industry plans, news, and policies are presented at a Global and regional level.

Table of Contents1 Market Overview2 Manufacturers Profiles3 Sales, Revenue and Market Share by Manufacturer4 Global Market Analysis by RegionsContinued

For Inquiry Before Buying This Report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4303566

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199 ; +91 895 659 5155

Read more:
Global Cryonics Technology Market 2020 SWOT Analysis, Drivers, Restraints, Growing Opportunities, Latest Trends, Applications and Forecast To 2025 -...

Recommendation and review posted by Bethany Smith

This week on The Trip podcast: Zoltan Istvan has come from the future with a message New Hampshire doesnt want to hear.

Here they are in the New Hampshire Secretary of States office, paying their thousand dollars to be on the official primary ballot. They are the lesser-known candidates, the dramatic fringe of each presidential primary election up here. And they are the stars of my quadrennial quixotic reporting project with photographer Shane Carpenter. And listen, they arent like Tom Steyer lesser-known, theyre like Vermin Supreme lesser-known, Mary Maxwell lesser-known, Zoltan Istvan lesser-known. Almost nobody knows these people, but theyre running anyway. This is the fifth primary that Shane and I have spent ducking out of mainstream campaign press events to track down the people who are just obsessive, idealistic, or imbalanced enough to think they should run for president, often with no money, no support, sometimes no platform really. Of course, the idea of a non-politician becoming president was distinctly more laughable before 2016, and now it doesnt seem that funny at all. But these candidates are something different, a wild bunch, far more entertaining and thought-provoking even than the scripted candidates. Shane and I just published a feature on the lesser-known and their radical approach to democracy on roadsandkingdoms.com; I hope youll take a look. But for now, in this episode, Ive got one of the most composed and compelling of this years fringe candidates, writer and transhumanist Zoltan Istvan. We drank some 15 year old Dalwinnie Scotch and talked about exoskeletons, being escorted at gunpoint from a megachurch, and why he let someone jam a horse syringe into his hand to give him a permanent bio-chip implant.

Here is an edited and condensed transcript from my conversation with Eva. Subscribers canlisten to the full episode here. If youre not on Luminary yet, subscribe and listen (and get a 7-day free trial) by signing uphere.

Nathan Thornburgh: What is transhumanism?

Zoltan Istvan: Transhumanism is a social movement, now of many millions of people around the world, that want to use science and technology to radically transform the human body and transform the human experience. Anything from exoskeleton suits to brain implants to even driverless cars. But whatever it is, its kind of the top 10% of the most radical technologies that are affecting the human race.

Thornburgh: You say there were many millions. Are these people who would actively knowingly define themselves as transhumanists, or you think its just aligned with the way that they look at the world?

Istvan: I think there are now probably millions that would say, if you ask them are you a transhumanist, they would now say, yes I am. When you ask them, is that what they consider themselves? Thats a little bit more challenging of a question. Google, for example, is probably the most transhumanist of all the companies out there, and they have the largest, what we call life extension company, a company worth billions of dollars, that wants to overcome aging. Its specifically designed to make people essentially live indefinitely. So we are getting to a point when you can now say millions and likely tens of millions who are supporters of the idea. Chinas probably leading the transhumanist movement in terms of innovationthey have the first designer baby babies and stuff like that. So there might be even many more.

But the word is just an umbrella term for many other ideas. Cryonics, singulariatism. Cyborgism. Singularity is the concept of transhumanists where they believe that AI will become so sophisticated that our human brains wont even be able to understand its sophistication. And at that point we get left behind.

The main goal of transhumanism is overcoming death with science and technology.

Thornburgh: The word itself, can you just break it down for me?

Istvan: Well, the Latin would say its beyond human.

Thornburgh: Okay, got it. All of our limitations are physicalchronological aging, mortality. Those are the things that youre going to supersede through technology.

Istvan: Basically, yes. And nobodys really sure like exactly what transhumanism means in terms of the specific agenda. Is it when a primate picked up a rock and made an axe millions of years ago, or is it a robot taking over a workers job, which of course is increasingly happening. Is that transhumanism, or is it brain implants? Nobody really knows, but whatever it is and it radical science is, is sort of changing the human species and the core of it is the microprocessor. It keeps evolving exponentially and we even have things like quantum computing now happening where, you know, that could revolutionize again, the microprocessor. So anything that applies to the human being, in terms of merging us with machines, is a transhuman event.

I think whats very important is that there are various versions of transhumanism. There are socialist transhumanists, there are libertarian transients like myself, and there are transceivers party transhumanism. Of course, Im, Im the founder of the transceivers party, but Im also now running as a Republican. But Ive also run as a libertarian, Ive said openly, I might run as a Democrat in the future. For me, its about the seed of transhumanism. You can take it whichever political way you want. Theres also Christian transhumanism, theres Buddhist transhumanist. So we want a worldwide movement. I want different factions. I want a decentralized idea of it. And I hope to influence it in terms of it grows and grows and grows. Because you have to understand about 80% of the worlds population believes in an afterlife. The main goal of transhumanism is overcoming death with science and technology. Were fighting 80% of the population. So its very important that we coalesce together as a movement that says we need to change that 80%. We need to change their mindset. And thats really where the cultural reform comes in, and why its so important to have a huge movements like environmentalism, where the trajectory is that one day we also become a billion person movement that really wants to move beyond our cultural heritage.

Thornburgh: So lets, lets posit success and you reach those 80% and flip them into transhumanists. What will that actually mean? Does that mean that they will vote for people who pour more resources into death-defying technologies or pass laws? What, practically, would having people be fired up about transhumanism do?

Istvan: Thats the best question. The great question. Thats exactly what Im trying to do. My main goal here with running for office and my main goal of spreading transhumanism is to get more money into the hands of the scientists who are making the movement happen. You have to understand, right now our United States Congress, all 535 members, all nine Supreme Court justices, believe in an afterlife, and they say they believe in God, so they have no real reason to pass laws to put money into the hands of the scientists who want to end aging and live indefinitely and upgrade ourselves to this new bionic future. Now the problem with that is if the entire government doesnt want to give money to it, it doesnt happen. Really only private industry does it. We need an American culture on board with transhumanism.

I run for office in hopes of saying, look, instead of giant military fighting warrants in Afghanistan and Iraq, were going to take that money and put it into creating a science-industrial complex in America dedicated to ending aging and upgrading the human being. Its a very different kind of way. Im interested in American healthcare, in terms of eliminating disease. And thats a very transhuman idea that our president right now doesnt share. A president whos cut the budget of the National Institute of Health.

Im running because, ultimately, I think that Trump has failed the most important part of America: the science and innovation part.

Thornburgh: Youre running as a Republican. This is your opponent.

Istvan: You gotta you gotta hit them hard on that. One thing Trump has done that hasnt been great is hes not only cut the budget of the National Institute of Health, but he hasnt made a culture where science really thrives. In China, its thriving. Chinas our main kind of competitor at this point. So probably within five years, China lead the world in AI and genetic editing. Its game over for America in terms of leadership, and who wants not authoritarian nation to be leading the world and in science and technology. So this is where I really fault Trump. In fact, this is why Im running. This is the singular reason Im running because, ultimately, I think that Trump has failed the most important part of America: the science and innovation part.

Thornburgh: What is your background? Take me way back.

Istvan: My career really began after I graduated from Columbia University, and I went into journalism at National Geographic. And so for five years I traveled around the world and I wrote something like 50 or 60 articles for their website, and also was on their National Geographic Today, show, doing a lot of documentary work. It was a great time in my life. I was in my twenties, I covered a lot of conflict zones, so saw some horrifying things. In Vietnam I was covering the demilitarized zone 20, 30 years after the war. And theres a bunch of rice farmers that now dig up bombs that were dropped in Vietnam from Americans, but theyre unexploded. They sell the metal. But to get there you have to go through these landmine-infested jungles. And I almost stepped on one. It freaked me out because my guide had to throw me out of the way and pointed to the ground. And after covering war zones for a while kind of gets in your head. And it was that moment in Vietnam when I said, you know, Im going to stop being a journalist and Im going to do something to try to overcome death. And of course transhumanism has been an ongoing movement since the 90s, and thats their primary job. Their primary purpose is to use science to overcome death.

Istvan: So I came home, joined the movement, wrote a novel, the novel did really well. It was called The Transhumanist Wager, became a bestseller, and it launched my career as a public figure. And because I was a journalist, I began writing some of the very first transhumanist columns. So Ive had an ability over six years to write over 230 opinion pieces and essays for major media, almost cheerleading transhumanism. Up until that point, no one had ever been optimistic about it. People had been kind of skeptical.

Thornburgh: That literally came from a near-death experience that you had.

Istvan: Its based on two or three years of covering other conflicts. Id covered the Sri Lanka conflict. I covered the Kashmir conflict between Pakistan and India. Id been doing some pretty harrowing stories and it made me, I think it kinda got in my head, I dont want to say its PTSD, but really it made me think, What if we could overcome death? And when it hit me that I could do this, I realized that this is why I want to dedicate my life to.

Thornburgh: Does transhumanism have any rights or rituals or holidays?

Istvan: Its secular. Its a very decentralized movement. A lot of the life-extension people are not interested in the robotics people, because life extension people want to biologically live longer, where the robotics people want to become machines and upload themselves. So even though they are both transhumanist and I like both groups, they dont really talk to each other. Then there are the biohackers, who are mostly young, tattooed people that are putting chips in. I have a chip in my hand. It opens my front door, starts a car, it sends a text message.

Thornburgh: You have this right now?

Istvan: I have it right now. You can touch it. Its right there. Push. Youll see. Youll feel a bump. Its a glass-enclosed microchip.

Thornburgh: Does that hurt when I press your chip?

Istvan: No. Its tiny. Its the size of a grain of rice. When you get these chip implants, you use a horse syringe you just put it in. Its kind of painful. But the chip itself is about the size of a grain rice.

Thornburgh: But that wasnt sexual what we just did?

Istvan: No. Its just a chip.

Thornburgh: How do you program this chip? Is this like a radio-frequency identification?

Istvan: Yeah. Unfortunately, the technology doesnt work with Apple phones, but it works with all Android. And so if you have an Android phone, you will actually be able to put it against my hand and then get my serial number. Of course, that freaks people out, because who has a serial number? But you can also put in medical information. So if youre unconscious and they find you, they can scan it. But in my case, Im a surfer and a jogger and when you go surfing you have to always hide your keys, and what a pain in the butt that is, because then someone can steal it when youre surfing and take your car. So in my case, its just great because all my keys are embedded into my hand and you can even do things like hold Bitcoin on it, but you cant pay it Starbucks yet.

Listen to the full episode at Luminary.

View post:
Zoltan Istvan: The Transhumanist Candidate - Roads and Kingdoms

Recommendation and review posted by Bethany Smith

CRISPR and CAS Gene Market 2020 Global Industry Research report presents an in-depth analysis of the CRISPR and CAS Gene market size, growth, share, segments, manufacturers, and technologies, key trends, market drivers, challenges, standardization, deployment models, opportunities, future roadmap and 2027 forecast.

Global CRISPR and CAS Gene Market 2020 Industry Research Report is an expert and inside and out examination on the flow condition of the Global CRISPR and CAS Gene industry. In addition, investigate report sorts the worldwide CRISPR and CAS Gene market by top players/brands, area, type and end client. This report likewise examines the different Factors impacting the market development and drivers, further reveals insight into market review, key makers, key received by them, size, most recent patterns and types, income, net edge with provincial examination and figure.

Get a sample copy of the report: https://www.coherentmarketinsights.com/insight/request-sample/2598

List Of TOP KEY PLAYERS in CRISPR and CAS Gene Market Report areCaribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Scope of Report:

The global CRISPR and CAS Gene market is anticipated to rise at a considerable rate during the forecast period, between 2020 and 2027. In 2020, the market was growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

This report covers present status and future prospects for CRISPR and CAS Gene Market forecast till 2027. Market Overview, Development, and Segment by Type, Application and Region. Global Market by company, Type, Application and Geography. The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses CRISPR and CAS Gene market trends, size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

CRISPR and CAS Gene Market Research Report provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

CRISPR and CAS Gene Market global industry research report is a professional and in-depth study on the market size, growth, share, trends, as well as industry analysis. According to the details of the consumption figures, the global CRISPR and CAS Gene market forecast 2027.

Market by Region:

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East and Africa (Saudi Arabia, South Africa etc.)

KEY BENEFITS FOR STAKEHOLDERS

The CRISPR and CAS Gene report provides extensive qualitative insights on the potential and niche segments or regions exhibiting favourable growth.

The report provides an extensive analysis of the current and emerging market trends and opportunities in the global CRISPR and CAS Gene market.

A comprehensive analysis of the factors that drive and restrict the growth of the CRISPR and CAS Gene market is provided.

An extensive analysis of the CRISPR and CAS Gene market is conducted by following key product positioning and monitoring the top competitors within the market framework.

The report provides detailed qualitative and quantitative analysis of current trends and future estimations that help evaluate the prevailing market opportunities.

The report also focuses on global major leading industry players of Global CRISPR and CAS Gene market providing information such as company profiles, product picture and specification, price, capacity, cost, production, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. With tables and figures helping analyze worldwide Global CRISPR and CAS Gene market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. The Global CRISPR and CAS Gene market development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Main Aspects covered in the Report

Overview of the CRISPR and CAS Gene market including production, consumption, status and forecast and market growth.

2016-2019 historical data and 2020-2027 market forecast.

Geographical analysis including major countries.

Overview the product type market including development.

Overview the end-user market including development.

Research objectives:

To understand the structure of CRISPR and CAS Gene market by identifying its various sub segments.

Focuses on the key global CRISPR and CAS Gene manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the CRISPR and CAS Gene with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of CRISPR and CAS Gene submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Purchase Copy of This Business Report: https://www.coherentmarketinsights.com/insight/buy-now/2598

Detailed TOC of Global CRISPR and CAS Gene Market Study 2020-2027:

1 Industry Overview

1.1 CRISPR and CAS Gene Industry

Figure CRISPR and CAS Gene Industry Chain Structure

1.1.1 Overview

1.1.2 Development of CRISPR and CAS Gene

1.2 Market Segment

1.2.1 Upstream

Table Upstream Segment of CRISPR and CAS Gene

1.2.2 Downstream

Table Application Segment of CRISPR and CAS Gene

Table Global CRISPR and CAS Gene Market 2020-2027, by Application, in USD Million

1.3 Cost Analysis

2 Industry Environment (PEST Analysis)

2.1 Policy

2.2 Economics

2.3 Sociology

2.4 Technology

3 CRISPR and CAS Gene Market by Type

3.1 By Type

3.1.1 Pigment Grade

Table Major Company List of Pigment Grade

3.1.2 Metallurgical Grade

Table Major Company List of Metallurgical Grade

3.1.3 Refractory Grade

Table Major Company List of Refractory Grade

3.1.4 Others

Table Major Company List of Others

3.2 Market Size

Table Global CRISPR and CAS Gene Market 2016-2019, by Type, in USD Million

Figure Global CRISPR and CAS Gene Market Growth 2016-2019, by Type, in USD Million

Table Global CRISPR and CAS Gene Market 2016-2019, by Type, in Volume

Figure Global CRISPR and CAS Gene Market Growth 2016-2019, by Type, in Volume

3.3 Market Forecast

Table Global CRISPR and CAS Gene Market Forecast 2020-2027, by Type, in USD Million

Table Global CRISPR and CAS Gene Market Forecast 2020-2027, by Type, in Volume

4 Major Companies List

4.1 Elementis (Company Profile, Sales Data etc.)

4.1.1 Elementis Profile

Table Elementis Overview List

4.1.2 Elementis Products & Services

4.1.3 Elementis Business Operation Conditions

Table Business Operation of Elementis (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)

Download PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/2598

At last, the report gives the inside and out examination of CRISPR and CAS Gene Market took after by above, which are useful for organizations or individual for development of their present business or the individuals who are hoping to enter in CRISPR and CAS Gene industry.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Name: Mr.ShahPhone: US +12067016702 / UK +4402081334027Email: [emailprotected]Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

Go here to read the rest:
CRISPR and CAS Gene Market Analysis And Growth Rate and Forecast to 2027 - Packaging News 24

Recommendation and review posted by Bethany Smith

CRISPR Therapeutics AG (CRSP) registered volume of 1243310 shares in most recent trading session as compared to an average volume of 1.08M shares. It shows that the shares were traded in the recent trading session and traders shown interest in CRSP stock. Listed Shares of the CRISPR Therapeutics AG (CRSP) moved down -1.26% to trade at $37.64 on Friday trading session. It has a market capitalization of $2.41B. Knowing about the market capitalization of a company helps investor to determine the company size, market value and the risk. The stock P/E & is 38.76 & EPS is $0.97 against its recent stock value of $37.64 per share.

First we will be looking for the boiling points and excitability of CRISPR Therapeutics AG (CRSP) stock, it purposes common trait for traders and value investors.

Volatility Indicators for CRISPR Therapeutics AG:

Volatility of the CRISPR Therapeutics AG remained at 10.39% over last week and shows 8.02% volatility in last month. In addition to number of shares traded in last few trading sessions volatility also tells about the fluctuation level of the stock price, commonly a high volatility is the friend of day traders. Volatility is also measured by ATR an exponential moving average (14-days) of the True Ranges. Currently, the ATR value of companys stock is situated at 3.97. Beta value is also an important factor that helps to know how much the Market risk lies with the trading of subjective stock. Beta indicator of this stock lies at 2.69. In case you dont know, when beta is higher than 1 then risk is higher and if beta is lower than 1, then risk will be low.

Now entering into the performance part of the article on CRISPR Therapeutics AG stock we should check the stocks actual performance in the past.

Performance of the CRSP Stock:

CRISPR Therapeutics AG revealed performance of -25.99% during the period of last 5 trading days and shown last 12 months performance of -2.36%. The stock moved to -21.65% in last six months and it maintained for the month at -34.82%. The stock noted year to date 2020 performance at -38.20% and changed about -42.67% over the last three months. The stock is now standing at -49.14% from 52 week-high and is situated at 12.19% above from 52-week low price.

Technical Indicators of CRISPR Therapeutics AG Stock:

RSI momentum oscillator is the most common technical indicator of a stock to determine about the momentum of the shares price and whether the stock trading at normal range or its becoming oversold or overbought. It also helps to measure Speed and change of stock price movement. RSI reading varies between 0 and 100. Commonly when RSI goes below 30 then stock is oversold and stock is overbought when it goes above 70. So as currently the Relative Strength Index (RSI-14) reading of CRISPR Therapeutics AG stock is 24.2.

Although it is important to look for trades in a direction of bigger trends when stocks are indicating an opposite short-term movement. Like looking for overbought conditions when bigger trend remained down and oversold conditions when bigger trend is up. In order to check a bigger trend for CRSP a 14-day RSI can fell short and considered as a short-term indicator. So in that situation a Simple moving average of a stock can also be an important element to look in addition to RSI.

The share price of CRSP is currently down -26.59% from its 20 days moving average and trading -31.32% below the 50 days moving average. The stock price has been seen performing along below drift from its 200 days moving average with -26.24%. Moving averages are an important analytical tool used to identify current price trends and the potential for a change in an established trend. The simplest form of using a simple moving average in analysis is using it to quickly identify if a security is in an uptrend or downtrend.

Profitability Spotlight for CRISPR Therapeutics AG:

Operating Margin which tells about what proportion of a companys revenue is left over after paying for variable costs of production such as wages & raw materials is noted at 16.10%. Net profit margin of the company is 23.10% that shows how much the company is actually earning by every dollar of sales.

Return on Investment (ROI) of stock is 4.90%. ROI ratio tells about the efficiency of a number of investments in a company. Return on Assets (ROA) which shows how much the company is profitable as compared to its total assets is observed at 9.60%. Return on Equity (ROE), which tells about the profitability of the corporation by evaluating the profit it generates in ratio to the money shareholders have invested, is noted at 11.70%.

The price-to-earnings ratio or P/E is one of the most widely-used stock analysis tools to determine a stocks valuation that also shows whether a companys stock price is overvalued/overbought or undervalued/oversold. If P/E is lower, then stock can be considered undervalued and if its higher then the stock is overvalued. Price to earnings P/E of the stock is 38.76.

Analysts Estimation on Stock:

The current analyst consensus rating stood at 2.2 on shares (where according to data provided by FINVIZ, 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Analysts opinion is also an important factor to conclude a stocks trend. Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $74.46.

See original here:
Digging CRISPR Therapeutics AG (CRSP) Stock, what Came to Know? - News Welcome

Recommendation and review posted by Bethany Smith

The clinic helps children at risk of developing heart disease in the future due to high cholesterol.

They can now attend a ground-breaking clinic run by the familial hypercholesterolemia (FH) service at York Teaching Hospital NHS Foundation Trust.

FH is an inherited condition which can lead to extremely high cholesterol levels and is passed down through families in the genes.

The FH service, led by Dr Chandrajay, Consultant in Chemical Pathology and Metabolic Medicine, and Claire Tuson, Familial Hypercholesterolaemia Specialist Nurse, has recently extended their service to include children and adolescents.

Claire explained: Research has shown that children with FH start to develop a build-up of fatty plaque in their arteries before the age of 10. Once diagnosed, FH is easy to treat so it makes sense to work with families as soon as possible.

Last year, with the support of Consultant Paediatrician Dr Dominic Smith, we extended gene testing to all children aged 10 years old and over, who have a parent affected with FH. Testing children for FH could prevent a potentially fatal heart attack or stroke.

The first six children from York and Scarborough that were identified with FH have recently attended our new Yorkshire and Humber joint paediatric clinic for children and their families, which launched at the end of January.

FH is estimated to affect 1 in 250 people in the UK, including over 56,000 children.

It is an inherited disorder of cholesterol and lipid metabolism, caused by an alteration in a single gene where people have higher levels of bad cholesterol levels from birth. If left undetected and untreated FH can lead to the early development of heart and circulatory problems.

Kiera Pickering, aged 12, and her brother Connor, aged 11, from Scarborough, were two of the first children to attend the clinic.

Claire added: Its a real breakthrough to be able to identify and treat children with FH so early. Alongside dietary and lifestyle advice to maintain a healthy body weight, children can be considered for statin therapy from as young as 10 years old.

"Statin treatment can not only prevent, but potentially reverse, the build-up of cholesterol and allow children and young people to live a perfectly healthy life.

Despite the availability of genetic testing, more than 85 percent of people with FH in the UK are undiagnosed.

The British Heart Foundation estimates that currently only around 600 children in the UK have been diagnosed with FH, meaning that thousands more are not on treatment and remain unaware of their future risk of heart disease.

For more information about the FH clinics contact claire.tuson@york.nhs.uk

See the original post:
Scarborough brother and sister, aged 11 and 12, with the genetic cholesterol condition FH are helped by new clinic - Whitby Gazette

Recommendation and review posted by Bethany Smith

What happened

Shares of Invitae (NYSE:NVTA) closed down 11.3% today as the broader market continued to fall. Investors are coming to grips that efforts to contain regional coronavirus outbreaks -- in fact, the novel coronavirus was just declared a global pandemic -- will have a significant negative impact on the global economy. And they're adjusting accordingly.

While there wasn't any company-specific news today, growth stocks tend to trade at healthy premiums. That makes them prime targets during market corrections -- and they tend to fall the hardest.

As of market close, shares of Invitae had settled to an 11.2% loss. The growth stock has now lost 1.7% since the beginning of 2020.

Image source: Getty Images.

The genetic testing company's growth-at-all-costs strategy has excited investors, who have generally been willing to forgo profits today in the hope of generating higher profits tomorrow. But global economic downturns have a funny way of shifting priorities around.

Invitae reported an operating loss of $244 million in 2019, which was double the total reported in 2018. While the business began 2020 with more than $391 million in cash to plow into expansion efforts and stomach continued losses, investors might be a little less willing to accept that much red ink during a recession, the odds of which have increased thanks to the coronavirus.

Growth stocks and volatility tend to go hand in hand in good times. The current market correction is simply amplifying those effects. The main takeaway for investors is that panicking or making emotional money moves isn't going to help the situation. Investors with a long-term mindset shouldn't necessarily expect the opportunity in genetic testing to be affected in the long run if or when a recession hits. Therefore, doing nothing is probably the best bet. If Invitae eases off its growth plans to preserve cash, then even better.

Read more from the original source:
Here's Why Invitae Stock Dropped Today - The Motley Fool

Recommendation and review posted by Bethany Smith

Jan Plumb has spent decades nurturing sphynx cats - the hairless felines - with an impressive 45 passing through her care over the years.

She currently owns six of her own who keep her busy alongside her role as secretary and welfare officer for The Sphynx Cat Club.

Jan, 75, raised her first cat after bringing it to these shores from the Netherlands in 1988 and then began breeding.

She now lives at home with her husband Les, 82, at their home in Christchurch, Dorset.

A fellow sphynx owner was forced to defend her wrinkly pet - as its face makes it look like it is constantly scowling.

Six-year-old Xherdan has a permanent angry-looking frown, leaving some people "a little bit scared".

But despite their poor reputation among some, Jan has loved the breed unconditionally for more than 30 years.

She said: "I'm very proud to have introduced them and of how they have become very popular.

"We started a society in 1991 [The Sphynx Cat Club] and now we have quite a big following.

"We got our first sphynx - Tulip - from the Netherlands in 1988.

"Our friends said they knew an owner after we had mentioned the cats. We had seen them in a magazine in 1984.

"We were then introduced and they said they had one for rehoming.

"We took it home and it was quarantined for six months before we could have it. We didn't have any problems from then on.

"[Sphynx cats] are proper lap cats. They are into everything, they can open doors and cupboards. They want to sleep in your bed. They are very friendly.

"There's nothing like a sphynx. Everyone that has got one has always ended up with more."

Expert Jan spent the next 32 years breeding and raising 45 cats.

She has become synonymous with the breed, founding the The Sphynx Cat Club and being heralded as an authority on all things related.

But she has slowed down in recent years and is now happy at home with just six: Meg, Mkai, Ruby, Willy, Perrrcy and Orion.

Jan said: "Sphynx cats can sell for anything from 700 to 1,200. That's because we have to do a lot of testing now.

"But it's no different to buying a Persian cat - you need genetic testing. That's why the price is like that.

"All of our cats now are neutered - I've been breeding for 32 years.

"As secretary and welfare officer I now deal with rehoming sphynx cats that come from abroad."

Although hairless cats have been around for generations, the sphynx is the first hairless breed that has been bred specifically for that trait.

The breeding programme began in 1966 in Ontario, Canada when a pet cat gave birth to a hairless male kitten.

However, most sphynx cats born today are descended from three hairless kittens found in Toronto in 1978.

It is thought there is now around 600 of the breed in Britain.

Originally posted here:
Woman who brought the first sphynx cat to Britain 30 years ago has defended them after they were labelled the ugliest in the world - Cambridgeshire...

Recommendation and review posted by Bethany Smith

TALLAHASSEE, Fla. As the end of the 2020 legislative session nears, the Florida House and Senate need to resolve key health-care policy and budget issues.

Here are seven big issues to watch:

NURSES: House Speaker Jose Oliva has made clear that his top priority is allowing advanced practice registered nurses to practice independently of physicians. The Senate is poised to offer a compromise that would allow the nurses to provide primary care and for certified nurse midwives to work autonomously. To qualify, advanced practice registered nurses would have to take at least 3,000 clinical practice hours in the five years before practicing autonomously. Its a scaled-back version of what the speaker wanted but more than what the Senate initially offered.

Why its in play Persistence. Oliva, R-Miami Lakes, never faltered in his push for independent practice. Its one of the few issues Oliva didnt get passed in 2019, and he is determined to get it done this year.

PHARMACISTS: In addition to giving more autonomy to nurses, Oliva has moved to broadly expand the scope of practice for pharmacists. Toward the end of the session, the House amended a proposal that initially would have allowed pharmacists to test and treat patients for the flu and strep throat and broadened it to allow pharmacists to treat people for chronic medical conditions. The Senate approved an amendment Tuesday and could send the bill back to the House as soon as Wednesday.

Why its in play This is one of a number of proposals that Oliva has championed during his tenure as House speaker, maintaining they will help lower health-care costs for the uninsured and keep people out of emergency rooms. Oliva has opposed expanding Medicaid coverage for uninsured people.

PEOPLE WITH DISABILITIES: Senate President Bill Galvano, R-Bradenton, was determined to increase funding for Medicaid services for people with developmental and intellectual disabilities. He has worked to increase funding for the Agency for Persons with Disabilities by $128 million in recurring general revenue in the upcoming fiscal year. The 2020-2021 budget also is expected to include $241 million to wipe out deficits the APD has accrued over the last two years. Galvano also would like to see passage of a bill (SB 82) that would make administrative changes in the iBudget program, which provides services that help people with disabilities remain in their homes and communities. Galvano hopes that will shore up the iBudget program and put to rest rumblings that it should be transitioned to managed care.

Why its in play Galvano told reporters in December that he has a real heart for this population.

GENETIC TESTING: The Senate inched closer Tuesday to passing a bill that would block life insurers and long-term care insurers from using genetic testing information when pricing policies. Before teeing up the bill (HB 1189) for a vote, the Senate approved an amendment that makes clear insurers could consider medical diagnoses included in medical records, even if the diagnoses were based on the results of genetic tests.

Why its in play The genetic testing issue has been a priority of incoming House Speaker Chris Sprowls, a Palm Harbor Republican who is a cancer survivor. Its unusual for incoming House speakers to file bills; they usually have other members to take on that task.

HOSPITAL FUNDING: The Senate has a plan to redirect money currently used to provide supplemental payments to hospitals that care for large number of low-income patients. The money would be targeted toward increasing base Medicaid rates for all hospitals. Hospital Corporation of America is leading the charge, arguing the change would allow Medicaid money to follow the patient and not the facility. The Safety Net Hospital Alliance of Florida has dubbed the supplemental payments the critical care fund, noting that the dollars are spent on 28 hospitals that provide the most charity care.

Why its in play This could be a take-home issue for Senate Appropriations Chairman Rob Bradley, a Fleming Island Republican who faces term limits this year. Bradley last year was successful at chipping away at the amount of supplemental hospital payments and wants more this year.

MEDICAID MANDATES: Florida administers its Medicaid program mostly through contracts with managed care plans after competitive bidding. The House wants to change Medicaid laws to require medical faculty plans and essential hospital providers to contract with all managed care plans or lose hundreds of millions of dollars in Medicaid funding.

Why its in play The issue stems from a contract dispute between Centene Health Plan, which operates in the Medicaid program as Sunshine Health Plan, and UF Shands Hospital in Gainesville, UF Health Jacksonville Hospital and physicians in the health systems network. The contract dispute has been settled, but the House speakers office doesnt want a repeat.

MEDICAID MANAGED CARE ENROLLMENT: The House also wants changes about automatic assignment of Medicaid beneficiaries to managed care plans. Such automatic assignment happens when beneficiaries dont choose plans. Potential changes include requiring the Agency for Health Care Administration secretary to certify that the states auto-assignment policy wont prevent managed-care plans from reaching enrollment levels necessary for sustainable operations.

Why its in play The changes would help Lighthouse Health Plan in the Panhandle, Vivida Health in Southwest Florida and Miami Childrens Health Plan in Southeast Florida, which are provider-sponsored networks that signed five-year contracts with the state in 2018. AHCAs current policy, the provider-sponsored networks argue, impedes their expansion in the market and benefits legacy managed-care plans.

View original post here:
7 big health care issues to watch as end of legislative session nears - WJXT News4JAX

Recommendation and review posted by Bethany Smith

A container ship arrives at Yusen Terminals at the Port of Los Angeles in Los Angeles, Calif., January 30, 2019. (Mike Blake/Reuters)

Over the past two weeks, America has faced the onset of a pandemic, an oil-price war, and a stock-market crash. In the face of these three crises, calls for economic stimulus are understandable, even expected. Yet the nature of the crises means that traditional fiscal stimulus measures could be counterproductive.

While there are some things policymakers could do, the most important thing is to avoid flash policy hasty reactions that create the illusion of doing something. Instead, they should work to reform or repeal policies that may have made the crises worse, and implement ones to make us more resilient in the future.

Traditional economic stimulus is inappropriate for a simple reason. It attempts to encourage more economic transactions between people. Increased economic activity is not necessarily desirable in the presence of a contagious pandemic, insofar as it encourages personal interactions.

Therefore, we should only rush to change policies on the basis of stimulus if they prevent effective response to the crisis, reduce resilience to changed economic behavior, or make the effects of the crisis worse than they would otherwise be.

An example of the last category is tariffs affecting supply chains. The administrations tariffs are aimed at changing how American businesses source materials and labor. If the tariffs are effective, they will put stress on supply chains as businesses shift their activities in response. And now, these supply chains are also under threat from the effects of the virus in supplier countries.

A temporary lifting of the tariffs will reduce the effects of that second stress and help keep many firms afloat. This would be preferable to announcing exemptions for firms under severe strain, a process that has proven difficult, bureaucratic, and prone to political influence.

Some policies have reduced effective responses. These include FDA regulations that prevent genetic testing firms from offering medical insights into individuals genetic traits, which have delayed the development and deployment of tests for COVID-19. That may have contributed to early spread of the pandemic. The FDA has lifted many of the restrictions, but any vaccine or cure still faces tremendous regulatory hurdles before it can be deployed.

Even accounting rules are a problem. For instance, SEC rules discourage the stockpiling of medical devices such as respirators, which are likely to be needed in large numbers and quickly exactly what stockpiles are meant for. Mark-to-market rules that helped exacerbate the last financial crisis are still in place, and could pose a major problem as assets turn illiquid with the market downturn.

Then there are policies that discourage resilience. For instance, delivery services are likely to be needed more than ever in the coming weeks. Yet many states are trying to put delivery services like GrubHub out of business by attacking their use of independent contractors.

Similarly, many states refuse to recognize out-of-state medical proficiency certifications. When doctors and nurses are desperately needed, these employment restrictions will cost lives. Fortunately, some states are leading the way to change this policy, such as Massachusetts and Florida.

Yet while there are things we can do, the most important may be to learn lessons for the next time this happens. Drone delivery is currently neither technologically feasible nor permitted by regulations. In a future pandemic, it could prove vital. So easing up on regulations that could delay experimentation and deployment could prove beneficial. Similar issues present for autonomous vehicles. There are examples like this across the board.

Moreover, we should take a good hard look at the institutions designed to tackle these challenges. The Centers for Disease Control and Prevention has spent less than 35 percent of its budget on fighting anything that can described as an infectious disease. Instead, it has focused on lecturing people about lifestyle. Theres a reason few listened when the health authorities warned against buying surgical masks. Narrowing the focus of the CDC back to infectious-disease control could help.

People want effective government during crises like these. That does not mean large government. If anything, governments sprawling nature has made it less responsive and effective in facing these genuine crises.

Fixing those problems isnt a question of doing something, spending more money, or having the right people in charge. It will involve a hard look at what government does and should and should not do. A resilient society requires a lean and flexible government. Flash policy wont achieve that.

The rest is here:
Pandemics, Stimulus, and the Limitations of Flash Policy - National Review

Recommendation and review posted by Bethany Smith

Cancer drivers converge on NOTCH

Cancer genomesequencing projects have emphasized the handful of genes mutated at high frequency in patients. Less attention has been directed to the hundreds of genes mutated in only a few patientsthe so-called long tail mutations. Although rare, these mutations may nonetheless inform patient care. Loganathan et al. developed a reverse genetic CRISPR screen that allowed them to functionally assess in mice nearly 500 long tail gene mutations that occur in human head and neck squamous cell carcinoma (HNSCC). They identified 15 tumor-suppressor genes with activities that converged on the NOTCH signaling pathway. Given that NOTCH itself is mutated at high frequency in HNSCC, these results suggest that the growth of these tumors is largely driven by NOTCH inactivation.

Science, this issue p. 1264

In most human cancers, only a few genes are mutated at high frequencies; most are mutated at low frequencies. The functional consequences of these recurrent but infrequent long tail mutations are often unknown. We focused on 484 long tail genes in head and neck squamous cell carcinoma (HNSCC) and used in vivo CRISPR to screen for genes that, upon mutation, trigger tumor development in mice. Of the 15 tumor-suppressor genes identified, ADAM10 and AJUBA suppressed HNSCC in a haploinsufficient manner by promoting NOTCH receptor signaling. ADAM10 and AJUBA mutations or monoallelic loss occur in 28% of human HNSCC cases and are mutually exclusive with NOTCH receptor mutations. Our results show that oncogenic mutations in 67% of human HNSCC cases converge onto the NOTCH signaling pathway, making NOTCH inactivation a hallmark of HNSCC.

Here is the original post:
Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling - Science Magazine

Recommendation and review posted by Bethany Smith

The Report titled: Global CRISPR And CRISPR-Associated (Cas) Genes Market Analysis: Production, Capacity, Sales, Revenue, Trends, Revenue Share, and Forecast till 2024

The authors of the CRISPR And CRISPR-Associated (Cas) Genes Market Report have done extensive study of the global CRISPR And CRISPR-Associated (Cas) Genes market keeping in mind the key aspects such as growth determinants, opportunities, challenges, restraints, and market developments. This analysis will enrich the ability of the companies involved in the global CRISPR And CRISPR-Associated (Cas) Genes market to make precise decisions. The report also emphasizes on the current and future trends in the global CRISPR And CRISPR-Associated (Cas) Genes market, which may bode well for the global CRISPR And CRISPR-Associated (Cas) Genes market in the coming years.

Get Free Exclusive Sample of this Premium Report at @ https://www.esherpamarketreports.com/request-sample/es-265564/

Table of Contents:

Section 1 CRISPR And CRISPR-Associated (Cas) Genes Product DefinitionSection 2 Global CRISPR And CRISPR-Associated (Cas) Genes Market Manufacturer Share and Market Overview2.1 Global Manufacturer CRISPR And CRISPR-Associated (Cas) Genes Shipments2.2 Global Manufacturer CRISPR And CRISPR-Associated (Cas) Genes Business Revenue2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market OverviewSection 3 Manufacturer CRISPR And CRISPR-Associated (Cas) Genes Business IntroductionSection 4 Global CRISPR And CRISPR-Associated (Cas) Genes Market Segmentation (Region Level)5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Segmentation (Product Type Level) Market Size 2014-20195.2 Different CRISPR And CRISPR-Associated (Cas) Genes Product Type Price 2014-20195.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market Segmentation (Product Type Level) AnalysisSection 6 Global CRISPR And CRISPR-Associated (Cas) Genes Market Segmentation (Industry Level)6.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Segmentation (Industry Level) Market Size 2014-20196.2 Different Industry Price 2014-20196.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market Segmentation (Industry Level) AnalysisSection 7 Global CRISPR And CRISPR-Associated (Cas) Genes Market Segmentation (Channel Level)

. And More

Click Here For Detailed Table Of Contents

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segment by Manufacturers, this report covers:

Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segment by Type, covers

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segment by Applications, can be divided into

Enquire before purchasing this report @ https://www.esherpamarketreports.com/pre-order-enquiry/es-265564

Key Highlights of CRISPR And CRISPR-Associated (Cas) Genes Market Report:

Reasons To Buy:

Purchase this Report with Full Access @ https://www.esherpamarketreports.com/purchase/es-265564/

Contact Us:

Name: Jason George

Email: [emailprotected]

Call :USA: +1 408 757 0510

Organization: eSherpa Market Reports

About Us:

eSherpa Market Reports is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segments.

Read the rest here:
CRISPR And CRISPR-Associated (Cas) Genes Market Insights, Status, Latest Amendments, Outlook, Trends, Growth, Scope, Size, Overall Analysis and...

Recommendation and review posted by Bethany Smith

The year is 1967. A British secret agent has been "frozen," awaiting the day when his arch nemesis will return from his own deep freeze to once again threaten the world. That day finally arrives in 1997. The agent is revived after 30 years on ice, and he saves the world from imminent destruction.

You'll probably recognize this scenario from the hit movie, "Austin Powers: International Man of Mystery" (1997). Cryonics also shows up in films like "Vanilla Sky" (2001), "Sleeper" (1973) and "2001: A Space Odyssey" (1968). But is it pure Hollywood fiction, or can people really be frozen and then thawed to live on years later?

The science behind the idea does exist. It's called cryogenics -- the study of what happens to materials at really low temperatures. Cryonics -- the technique used to store human bodies at extremely low temperatures with the hope of one day reviving them -- is being performed today, but the technology is still in its infancy.

In this article, we'll look at the practice of cryonics, learn how it's done and find out whether humans really can be brought back from the deep freeze.

Continue reading here:
How Cryonics Works | HowStuffWorks

Recommendation and review posted by Bethany Smith

We are born, we live, and we die. For most, this is the expected life cycle of our complex human existence. However, there are idealists and hopefuls on the far end of the spectrum who beg to differ. Through the aid of progressive science and technology, scientists and experts have discovered unimaginable ways to enhance and elevate the human condition and the world we live in. From developing artificial intelligence, assistive technology, bioengineering, to pushing the boundaries of knowledge to find the antidote to mortality. With the proper tools and research, futurists believe that death shouldnt be the culmination of life, but rather a disease that is treatable and reversible.

RANDOM MEDIA

Filmmaker Johnny Boston had the privilege of meeting and developing a meaningful friendship with an extraordinary man beyond his years, FM-2030, at the tender age of ten. He ignited Bostons curiosity and shaped his critical thinking from then on. When the news broke out that scientists were on a mission to reanimate FM-2030s cryogenically preserved brain for the first time, he strips himself of all his fears and reservations, daringly crossing lines to capture the highly controversial and monumental event unfold through his sci-fi documentary entitled 2030 (2018).

One of the pioneers of this philosophy is renowned futurist and transhumanist, FM-2030. No, he is not a bionic man nor from outer space as his name suggests. He is very human, just like us. In the 70s, he changed his legal name from Fereidoun M. Esfandiary to FM-2030 to strongly reflect his revolutionary ideologies and confidence in a post-humanistic world.

In his own words, conventional names define a persons past: ancestry, ethnicity, nationality, religion. I am not who I was ten years ago and certainly not who I will be in twenty years. The name 2030 reflects my conviction that the years around 2030 will be a magical time. In 2030 we will be ageless and everyone will have an excellent chance to live forever. 2030 is a dream and a goal.

futurists believe that death shouldnt be the culmination of life, but rather a disease that is treatable and reversible.

His radical forward-thinking and belief in the technological advancements in medicine, engineering, and computer science enthused him to envisage a world that will be free from the norms, principles, and values that bound todays society, human limitations and adversities, scarcity of energy and resources, and the birth of a human race that will live on for eternity.

Unfortunately, FM-2030 succumbed to pancreatic cancer, but his death was only the beginning of his extraordinary journey to immortality. Since 2000, FM-2030s brain has been vitrified and cryogenically preserved at one of the worlds leading cryonic facilities, Alcor Life Extension Foundation, in hopes of being resurrected or reanimated in the future.

RANDOM MEDIA

2030 (2018) is a thought-provoking and enlightening narrative that explores the unconventional, liberal, and scientific approach to the fate of our existence. The documentary follows Boston as he embarks on an arduous journey to seek the true meaning of humanity and this innovation through the eyes of his loved ones, colleagues, and experts, while reflecting and preparing for FM-2030s reanimation, which if carried out successfully, would be the first case of cryonically-preserved human revival.

Boston enthusiastically brings up his bright idea of filming the process to FM-2030s life partner, Flora Schnall, only to find out that she vetoes his proposition and wants to keep the reanimation top secret despite FMs approval. At the cryonics lab, Schnall introduces Boston to Sebastian Smith, a doctor and student of FM at The New School who will lead the reanimation team. It was clearly established from the get-go that this endeavor would be strictly private. But being the ambitious and rebellious filmmaker that he is, he stops at nothing. Eager to document FMs return, he used covert body cameras to put all conversations, meetings, and interviews on record. This bold move revealed a plethora of classified information that only elevated and sustained the tension and conflict of the story.

As soon as the credits have rolled, I found myself ten open tabs deep into my research.

For people who are just learning about this concept, 2030 (2018) engagingly and effectively provided an in-depth and digestible understanding of the world of cryonics. It responsibly dissected and presented insightful opinions and perspectives of neuroscientists, cryonicists, robotics engineers, psychotherapists, transhumanists, and ethicists that are crucial in understanding the science behind this process. The most remarkable and fascinating part, that hints at the possibility for reanimation, was the trial of Cleon, a cryo-preserved pig who was successfully reanimated after six months.

While it does serve its purpose of being informative and educational, I must admit that this documentary was a tad bit dramatized and methodically structured. Instances such as Boston and Schnalls emotional falling out, Smiths animated character, a doctor turned whistleblower who mysteriously disappeared, and cryptic file transfers of confidential information. Towards the end, all hope was lost for Boston as Schnall pulled the plug on the project and forbids him to attend the reanimation. However, a plot twist ensues when Boston discovered Smiths illness and intention to use FM as a guinea pig for the main event Smiths eventual reanimation. Together, they confront Smith about this revelation and completely deauthorize FMs reanimation, putting a halt to this mission.

As someone who resolutely believes that everything has a beginning, middle, and end, I couldnt help but roll my eyes at the absurdity of restoring a frozen deceased body back to life, which cryonics indisputably claims to achieve. But Bostons documentary somehow effectively steers the skeptics in the right direction to give it the benefit of the doubt. As soon as the credits have rolled, I found myself ten open tabs deep into my research. No matter what its intended purpose, 2030 (2018) has succeeded in raising awareness and disclosing vital knowledge about a highly complex system that could change humankind forever.

The documentary at its core inspires us to reevaluate our purpose, beliefs, and hopes for the future. It imparts new wisdom and encourages us to have an open mind so that we are able to empathize with people who choose to walk this path.

2030 (2018) is distributed by Random Media and was released on multiple digital platforms and on-demand February 25th, 2020.

See the article here:
Playing God: Did Futurist FM-2030 Crack the Code to Immortality? - LIVING LIFE FEARLESS

Recommendation and review posted by Bethany Smith

Cryonics TechnologyMarket reports provides a comprehensive overview of the global market size and share.Cryonics Technologymarket data reports also provide a 5 year pre-historic and forecast for the sector and include data on socio-economic data of global. Key stakeholders can consider statistics, tables & figures mentioned in this report for strategic planning which lead to success of the organization

Get Sample Copy of this Report https://www.orianresearch.com/request-sample/1011142

What You Can Expect From Our Report:

Purchase Directly@ https://www.orianresearch.com/checkout/1011142

The report firstly introduced the Cryonics Technology basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis. The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the Cryonics Technology market.

The key players covered in this study, Praxair, Cellulis, Cryologics, Cryotherm, KrioRus, VWR, Thermo Fisher Scientific, Custom Biogenic Systems, Oregon Cryonics, Alcor Life Extension Foundation, Osiris Cryonics, Sigma-Aldrich, Southern Cryonics

Market segment by Type, the product can be split intoSlow freezingVitrificationUltra-rapid

Market segment by Application, split intoAnimal husbandryFishery scienceMedical sciencePreservation of microbiology cultureConserving plant biodiversity

Global Cryonics Technology Industry 2020 Market Research Report is spread across 92 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

What to Expect From This Report on Cryonics Technology Market:

The developmental plans for your business based on the value of the cost of the production and value of the products, and more for the coming years.

A detailed overview of regional distributions of popular products in the Cryonics Technology Market.

How do the major companies and mid-level manufacturers make a profit within the Cryonics Technology Market?

Estimate the break-in for new players to enter the Cryonics Technology Market.

Comprehensive research on the overall expansion within the Cryonics Technology Market for deciding the product launch and asset developments.

Regions Covered in Cryonics Technology Market are:-

North and South America

Europe

China

South Korea

Japan

India

Research Objectives of Cryonics Technology Market:

To study and analyze the global Cryonics Technology consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2020, and forecast to 2026.

To understand the structure of Cryonics Technology market by identifying its various sub segments.Focuses on the key global Cryonics Technology manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Cryonics Technology with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Cryonics Technology submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Major Points from Table of Contents1 Study Coverage1.1 Cryonics Technology Product Introduction1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.4.1 Global Cryonics Technology Market Size Growth Rate by Type1.4.2 Specialty Gas Grade (Low Purity)1.4.3 Research Grade (High Purity)1.5 Market by Application1.5.1 Global Cryonics Technology Market Size Growth Rate by Application1.5.2 Nuclear Application1.5.3 Non-Nuclear Application1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Cryonics Technology Production2.1.1 Global Cryonics Technology Revenue 2014-20262.1.2 Global Cryonics Technology Production 2014-20262.1.3 Global Cryonics Technology Capacity 2014-20262.1.4 Global Cryonics Technology Marketing Pricing and Trends2.2 Cryonics Technology Growth Rate (CAGR) 2020-20262.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)2.3.2 Key Cryonics Technology Manufacturers2.3.2.1 Cryonics Technology Manufacturing Base Distribution, Headquarters2.3.2.2 Manufacturers Cryonics Technology Product Offered2.3.2.3 Date of Manufacturers Enter into Cryonics Technology Market2.4 Market Drivers, Trends and Issues

3 Market Size by Manufacturers3.1 Cryonics Technology Production by Manufacturers3.1.1 Cryonics Technology Production by Manufacturers3.1.2 Cryonics Technology Production Market Share by Manufacturers3.1.3 Global Market Concentration Ratio (CR5 and HHI)3.2 Cryonics Technology Revenue by Manufacturers3.2.1 Cryonics Technology Revenue by Manufacturers (2014-2020)3.2.2 Cryonics Technology Revenue Share by Manufacturers (2014-2020)3.2.3 Global Cryonics Technology Market Concentration Ratio (CR10 and HHI)3.3 Cryonics Technology Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans

4 Cryonics Technology Production by Regions

5 Cryonics Technology Consumption by Regions

6 Market Size by Type

7 Market Size by Application

8 Manufacturers Profiles

9 Production Forecasts

10 Consumption Forecast

11 Upstream, Industry Chain and Downstream Customers Analysis

12 Opportunities & Challenges, Threat and Affecting Factors

13 Key Findings

14 Appendix

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Customization Service of the Report:

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

View post:
Cryonics Technology Market 2020: Qualitative Analysis of the Leading Players and Competitive Industry Scenario - 3rd Watch News

Recommendation and review posted by Bethany Smith

New York, March 13, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Induced Pluripotent Stem Cells Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025" - https://www.reportlinker.com/p05874276/?utm_source=GNW 6% over the forecast period from 2019-2025. The study on induced pluripotent stem cells market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on induced pluripotent stem cells market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global induced pluripotent stem cells market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porters five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global induced pluripotent stem cells market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings1) Drivers Increased government fundings and rising industry focus on the development of novel therapies Rising interest in stem cell therapy2) Restraints High the cost associated with storage3) Opportunities Growing applications of iPS cells in several biopharmaceutical applications provides extensive potential to the key players in the market

Research Methodology

A) Primary ResearchOur primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include1. Key Opinion Leaders associated with Infinium Global Research2. Internal and External subject matter experts3. Professionals and participants from the industry

Our primary research respondents typically include1. Executives working with leading companies in the market under review2. Product/brand/marketing managers3. CXO level executives4. Regional/zonal/ country managers5. Vice President level executives.

B) Secondary ResearchSecondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include1. Company reports and publications2. Government/institutional publications3. Trade and associations journals4. Databases such as WTO, OECD, World Bank, and among others.5. Websites and publications by research agencies

Segment CoveredThe global induced pluripotent stem cells market is segmented on the basis of derived cell type, application, and end user.

The Global Induced Pluripotent Stem Cells Market by Derived Cell Type Fibroblasts Amniotic Cells Hepatocytes Keratinocytes Others

The Global Induced Pluripotent Stem Cells Market by Application Drug Development Regenerative Medicine Toxicity Testing Academic Research

The Global Induced Pluripotent Stem Cells Market by End User Research Organizations Hospitals Biopharma Industries

Company Profiles Astellas Pharma Inc. Fate Therapeutics Inc. FUJIFILM Holdings Corporation Evotec SE Japan Tissue Engineering Co., Ltd ViaCyte, Inc. Vericel Corporation Bristol-Myers Squibb Company Aastrom Biosciences, Inc. Acelity Holdings, Inc.

What does this report deliver?1. Comprehensive analysis of the global as well as regional markets of the induced pluripotent stem cells market.2. Complete coverage of all the segments in the induced pluripotent stem cells market to analyze the trends, developments in the global market and forecast of market size up to 2025.3. Comprehensive analysis of the companies operating in the global induced pluripotent stem cells market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.Read the full report: https://www.reportlinker.com/p05874276/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More here:
Global induced pluripotent stem cells market is expected to grow with a CAGR of 8.6% over the forecast period from 2019-2025 - GlobeNewswire

Recommendation and review posted by Bethany Smith

By Lisa Rapaport

(Reuters Health) Young men who care about their sperm quality might want to lay off the cheeseburgers and fries, according to a new study that links a typical Western diet with a lower sperm count.

Men in the study who ate a mostly Western diet characterized by pizza, fries, sweets, sodas and red and processed meats typically had a lower sperm count by about 26 million than men who ate far less of these unhealthy foods. With a Western diet, men also had lower levels of reproductive hormones needed for optimal fertility.

Conversely, men with the healthiest eating habits with lots of fish, chicken, vegetables, fruits, and water typically had a sperm count 43 million higher than those who ate the lowest amounts of these foods.

Your sperm is what you eat, said coauthor Dr. Feiby Nassan of the Harvard T. H. Chan School of Public Health in Boston.

Diets rich in seafood, poultry, nuts, whole grains, fruits and vegetables provide antioxidants and omega-3 fatty acids that are essential for good sperm production, Nassan said by email.

Our results suggest the possibility of using dietary intervention as a possible approach to improve sperm quality of men in reproductive age, Nassan said.

A normal sperm count can range from 15 million to 200 million sperm per milliliter of semen.

Sperm quality and certain sex hormone levels have decreased substantially over the past few decades, driven in part by worsening diets in many parts of the world, the researchers note in JAMA Network Open.

The current analysis included 2,935 healthy men in Denmark, ages 19 or 20 on average. Researchers divided them according to how closely their diets matched four patterns: a Western diet; a healthy diet described as a prudent pattern of eating; a so-called open-sandwich diet consisting of whole grains and lots of cold cuts, fish, condiments, and dairy; and a vegetarian-like diet with lots of veggies, soy, milk, and eggs and little if any red meat or chicken.

Total sperm count with the Western diet was significantly lower than with any of the other three eating patterns.

The study wasnt designed to prove whether diet directly affects sperm or fertility. Researchers also focused on young, healthy men who might not yet be trying to conceive, and they didnt examine what happened in older men who wanted to become fathers.

Still, the study adds to evidence suggesting a healthy diet is good for mens reproductive health, Dr. Muhammad Imran Omar of the University of Aberdeen in the UK said by email.

And, men, like women, should try to adopt a healthy diet, cut back on alcohol and stop smoking months before they want to start trying for a baby.

However, men should be aware that it takes three months to produce sperm, said Allan Pacey, a researcher at the University of Sheffield in the UK who wasnt involved in the study.

If a man alters his diet on a Friday it wont improve his sperm by Monday, Pacey said by email.

SOURCE: https://bit.ly/2VQrYmr JAMA Network Open, online February 21, 2020.

See the rest here:
Even among young men, healthier diet tied to higher sperm counts - Physician's Weekly

Recommendation and review posted by Bethany Smith

Simple methods to take care of your body and business.

Opinions expressed by Entrepreneur contributors are their own.

The following article is written by Ben Angel. Author of the book, Unstoppable: A 90-Day Plan to Biohack Your Mind and Body for Success. Buy it now from Amazon | Barnes & Noble | iBooks | IndieBound. And be sure to order The Unstoppable Journal, the only journal of its kind based on neuroscience, psychology and biohacking to help you reach your goals.

As we all grow accustomed to life in the age of novel coronavirus COVID-19, and scientists continue working on antivirals and vaccines,many experts are suggestingthe public take a holistic approach to general health maintenance. And as biohackers know better than most, positiveimmune responsecan beessential to staying healthy.While the following suggestionsare not ways to prevent you from contracting the virus, they areeasyways to keep yourself as healthy as possible.

As noted in a recent studyfrom the Sleep Foundation, "Without sufficient sleep, your body makes fewer cytokines, a type of protein that targets infection and inflammation, effectively creating an immune response. Cytokines are both produced and released during sleep, causing a double whammy if you skimp on shut-eye. Chronic sleep loss even makes the flu vaccine less effective by reducing your bodys ability to respond."

onsequently, the study advises taking two 30-minute-or-less daily napsto help mitigatesleep deprivation's effects on the immune system. But if you're having a difficult time getting to sleep, you can try the many binaural beats found on YouTube (Jody Hattons Power Napsis a good place to start)to help grab some winks on your coffee break.

Getting rid of sugar biohacks your immune system by removing a food source for the bad bacteria in your gut that can kill off your good bacteria. Autoimmune problems anddigestive issues are telltale signs of gut imbalance. Ideally, your gut should be 85 percentgood bacteria or probiotics.

You can check for gut dysbiosis through gut-microbiome tests from companies like Thryve Inside, as well as take stock of what youre eating on a daily basis. Fermented foods like sauerkraut, kombucha and kimchi can all help repopulate the good bacteria in your gutas well, leaving you with more energy and vitality.

Its been known for centuries that fasting has been used as a health protocol. Paracelsus, a great healer in the Western tradition, wrote 500 years ago that,Fasting is the greatest remedy, the physician within. In 2014, Dr. Valter Longo of the University of Southern California discovered that fasting for threedays (having nothing but water) could essentially reset the immune system. As summarized on Humann.com, holding off on eating for at least 16-18 hours after your last meal allowsyour bodys attention to become "focused on the current immune cells, recycling them and getting rid of the damaged cells. This means that during the fast, your body is running lean and mean with its white blood cells."

This practice, of course, should only be done if youre already healthy. But provided that's the case, who wouldnt want more time to completeprojects at workand get healthier at the same time?

Stress causes an inflammatory response within the body that can greatly affect your fight-or-flight response by releasing too much of the stress hormone cortisol. It also leaves us more vulnerable to infections and disease, both in and out of the office. That's why mindfully meditating has become a must forany biohacking entrepreneurs. There arevarious forms of mindfulness practices, ranging from the slow-moving poses ofyoga and tai chi to myriad breathing techniques. And arecentstudyinTranslational Psychiatry adds that "there seems to be something intrinsic about meditation itself that can shift gene expression and even boost mood over time."

Many airlines are now monitoring travelers's health before and after flights. According to the CDC, those with no respiratory symptoms do not need to wear a medical mask. The CDC also recommends the use of masks for people who have symptoms of the virus and for those caring for individuals who have symptoms, such as cough and fever.

In his book, Cockpit Confidential, author Patrick Smithstates that in an airplane, Between 94 and 99.9 percent of airborne microbes are captured, and theres a total changeover of air every two or three minutes far more frequently than occurs in offices, movie theatersor classrooms.

This is all the more reason why taking your vitamins during stressful times is important, since many of our essential minerals and vitamins can become depleted during stress. Vitamins C,B and D, as well as zinc,all support your immune system. Research shows that zinc alone can help keep inflammation at bay so that your immune response is better supported.

Related: Coronavirus and a Looming RecessionHow to Raise Capital in Uncertain Times

Although we are in uncertain times, we dont have to wait to see if we are healthy enough to overcome any type of sickness or disease. By implementing some of these holistic steps to boost your immune system, it will inevitably be a win-win situation for not only your health and well-being, but for keeping your business running like a well-oiled machine.Bottom line: Dont panic, and take advice from the medical professionals who are specialists in this area.

This article solely reflects the opinion of the author and is not intended as an alternative to recommended official government guidelines. For more updates and information about the novel coronavirus, visit the CDC's website.

Are you ready to become unstoppable?

Visit http://www.areyouunstoppable.com and take your FREE 60-second online quiz now. By answering a series of simple questions, my software will analyze your results and provide you with a comprehensive report that will indicate your identity type and lead you to the tools and tips you need to close that gap between who you are and who you could be. Take the quiz to get started!

Visit link:
How to Boost Your Immune System During the Coronavirus Outbreak - Entrepreneur

Recommendation and review posted by Bethany Smith

The Covid-19 crisis is triggering global fears that are beginning to cross over into panicky feelings (especially if you or a loved one is over 80 and in a nursing home). That state of mind is called dread.

In this piece I will endeavor describe and explain what is going on in your brain and mind when you are in a state of dread.

A disclaimer. It is empirically (i.e. observationally and experience) based and neither evidence nor research based. In fact, I would ask such researchers to weigh in and make what follows more scientifically sound.

Nevertheless, I hope it will help you better understand what is going on inside you and in so doing be calming, reassuring to you and even inform you and others who read this about what might psychologically stem the tide of rising fears.

When youre fearful, its because the way you have been living your life and the reassuring assumptions about the world that keep you calm enough to make good decisions are suddenly upended. Its as if the beliefs you have that help you to maintain your daily sanity and orientation are suddenly ripped away and the future you were living into, is suddenly extremely gone.

When thisoccurs a stress hormone called cortisol is released by your adrenal glands toalert your body to doing what it needs to do to survive. Added to that isanother hormone secreted by your adrenal glands called adrenaline whichdirectly gets your body physically ready to deal with stress which can comefrom either fear or excitement.

As your cortisol and adrenaline rise, so too does dread and a part of your brain which deals with emotions, also referred to as your mammalian/middle brain (more on that later), called your amygdala becomes highly activated.

Your amygdala is a combination emotional sentinel and point guard rolled into one. If your amygdala senses this is a time for survival it can hijack you away from accessing the prefrontal part of your cerebral cortex, that helps you assess as situation, consider options and then make rational decisions. The hijack actually coincides with more blood flow going into your middle and then lower/reptile brain to take action to survive and away from going to your upper/human brain where you can think and consider options.

When an amygdala hijack causes blood flow to go more to your middle and lower brains an interesting thing happens to something called your Triune Brain.

Paul MacLean was a physician and neuroscientist who first coined the phrase Triune Brain to go along with his theory that we have three brains: an upper/human/thinking brain, a middle/mammalian/emotional brain, and a lower/reptile/fight or flight brain. He postulated that they developed through evolution and have learned to align with each other when were functioning at our best. They are kept in alignment when they are all aimed a future that were living into.

However, when a relatively predictable future becomes completely uncertain and an amygdala hijack occurs with resultant blood flow change, your three brains can become decoupled with each brain functions separately from each other. We even have metaphors that reflect that: wigged out, unglued, out of sorts, out of you mind, freaked out, etc. When that happens, you have entered into a state of dread.

When that amygdala hijack occurs and each of the three brains fend for themselves, the upper/human/thinking brain can flip into obsessive thinking (thinking the same thoughts repetitively), the middle/mammalian/emotional brain can flip into high anxiety (with dread causing it to flirt with terror and then panicky feelings), and the lower/reptilian/fight-flight-freeze can flip into compulsive repetitive behaviors where you run, become angry or just freeze in your tracks.

When thisoccurs, you have what I refer to as Triunal Rigidity, where the three brainshave become rigidly connected to each other after the future they were aimingtowards gets stripped away. Triunal Rigidity is what makes your mind brittleand prone to feeling fragile as if it could break and shatter (= lose yourmind). It is that feeling of brittleness leading to fragility leading toshattering that can cause a sense of impending doom, terror and panic.

What is thesolution to this?

That is what Irefer to as Triunal Agility where whatever uncertainty and unpredictability isthrown at you, you can pivot, realign with what you need to do and then takeaction. And if that action is a littleoff, your Triunal Agility can enable you to re-pivot and realign some more.

What is necessary to transform your brittle Triunally Rigid mind that is consumed by dread into a rapidly adapting Triunally Agile mind that can reason?

Lets use theCoronavirus as an example.

It is the following information regarding Covid-19:

Generalized non-factually founded reassurances or worse, consistently inconsistent messages from President Trump who doesnt appear to grasp the situation or even understand the virus rather than being assuring actually appear to increase uncertainty and dread, because he makes it difficult to believe him.

The person best qualified to deliver the message must be highly trained, experienced in such matters, calm, clear, with specific directions and someone we can believe. Dr. Anthony Fauci who is head of the National Institute of Allergy and Infectious Diseases appears to be the current go to person to advise us.

See Glossary of terms above

Read this article:
When Dread Becomes You - Thrive Global

Recommendation and review posted by Bethany Smith

CRISPR-Cas9 is described as a cut-and-paste technique that targets and removes specific sections of DNA. Different DNA can then be pasted in its place.Flickr/Andy Leppard

Our genes are the basic functional units of heredity that code for proteins which determine our characteristics. Variations in genomes arise due to internal cell processes, such as mistakes made when copying DNA, or external factors such as ultraviolet radiation from sunlight. Beyond this, the ability to selectively and artificially modify genes to add, remove or change traits is a developing field with huge potential but also worrying ethical implications. As of February 2020, new steps have been taken towards using this medical technology in the clinic and so these ethical concerns require urgent attention.

What is CRISPR-Cas9?

CRISPR-Cas9 is described as a cut-and-paste technique that targets and removes specific sections of DNA. Different DNA can then be pasted in its place.

This works using specific regions of DNA called Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR). These DNA sequences are recognised by an endonuclease enzyme called Cas9, using its own guide RNA. This allows Cas9 to cut both strands of DNA at specific points in the genome.

Where did the idea for CRISPR-Cas9 come from?

The principle for CRISPR-Cas9 gene editing was derived from a protection measure in certain bacteria against a group of viruses called bacteriophages. Cas9 retains genetic information from previous virus infections in the form of its guide RNA, which it then compares to foreign viral DNA of subsequent infections. If the foreign DNA matches the RNA, then Cas9 cleaves the invading DNA.

Can CRISPR save lives?

In February 2020, a research team in the USA safely edited the immune systems of three patients suffering from cancer without any negative side effects. CRISPR-Cas9 was used to target multiple genes in T cells, a type of immune cell. The modifications led to certain changes that stimulated the immune system to specifically recognise and attack cancerous cells.

Cancer is the second leading cause of death globally, accounting for over 15% of deaths. Any new approach that could provide a new perspective on cancer treatment is clearly hugely important.

However, there are some disadvantages to consider. Cas9 has a relatively high accuracy rate but the possibility of offshooting still exists - when the target gene is not hit correctly. This can lead to abnormal gene function and expression. Additionally, Cas9 and the RNA it uses to recognise CRISPR sequences is relatively large and so delivery into the nucleus of the cell, where the DNA is located, can be difficult.

What about editing at the germline?

CRISPR-Cas9 can be used to edit genomes at the germline level, meaning that any modifications made will be present in all cells of the organism involved, and will be passed onto offspring. This may initially sound like a good thing - any positive changes made, such as removing a gene variant associated with increased cancer risk, can benefit all future generations with just one change. However, editing at the germline raises complicated ethical questions. Is it morally acceptable to choose what characteristics we give our offspring? Even if this starts in the context of disease prevention, it may well be a slippery slope leading to the removal of any trait viewed as undesirable, pushing society into a eugenics movement - a set of practices that work to improve the genetic quality of the human population.

Many fear that this could widen the gap between the rich and poor, if only some members of society are able to afford CRISPR editing.

He Jiankui and the backlash regarding designer babies

In November 2018, He Jiankui presented results of his work in creating genetically edited babies. Jiankui used CRISPR technology to edit DNA in human embryos to make them less susceptible to HIV. This is an example of how CRISPR can be used to prevent future disease, but Jiankuis actions have been heavily condemned and have led to his prosecution on the grounds that he breached scientific and ethical conduct. The technology employed was deemed too advanced to be used on newborn babies and the risk-benefit ratio was deemed inappropriate, as the babies would not have been immediately at high risk for HIV.

Beyond Healthcare

CRISPR can also be used in agriculture, to create compact plants with less sprawling bushes, larger fruits that can ripen at the same time, higher vitamin C levels and many other characteristics that can either aid in crop growth or improve crop quality. Increased crop quantity could be hugely beneficial as the global population continues to rise and higher vitamin content can help to ensure that the prevalence of deficiency diseases is reduced.

The Future of CRISPR

There is still much scope to improve CRISPR techniques. In Zurich, Switzerland, Cas9 has been replaced with Cas12a (a similar enzyme) that can allow for targeting of lots of genes with a smaller RNA molecule. This is likely to be faster and more efficient, and may help to solve the problem of reaching the DNA in the cells nucleus. Tufts University in the USA has also attempted to improve CRISPR by using a different delivery method for Cas9 that could allow it to diffuse straight through the cell membrane.

Even if we were to achieve optimal function of the CRISPR-Cas 9 technique, this does not mean that CRISPR use is undisputedly positive. Gene editing techniques come with a range of ethical challenges, many of which may remain unresolved even as the technology is coming ever closer to widespread use.

More:
CRISPR-Cas9: Should we be able to edit our genes? - Varsity Online

Recommendation and review posted by Bethany Smith

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Thursday, shares of CRISPR Therapeutics AG (Symbol: CRSP) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $38 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 27.7. A bullish investor could look at CRSP's 29.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of CRSP shares:

Looking at the chart above, CRSP's low point in its 52 week range is $33.55 per share, with $74 as the 52 week high point that compares with a last trade of $40.11.

Find out what 9 other oversold stocks you need to know about

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Follow this link:
CRISPR Therapeutics Enters Oversold Territory (CRSP) - Nasdaq

Recommendation and review posted by Bethany Smith

Shares of Crispr Therapeutics AG (NASDAQ:CRSP) have been assigned a consensus rating of Buy from the twenty ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $74.42.

Several equities analysts have commented on CRSP shares. Stifel Nicolaus started coverage on Crispr Therapeutics in a research report on Wednesday, March 4th. They set a hold rating and a $52.00 price objective for the company. Citigroup raised their price objective on Crispr Therapeutics from $28.00 to $31.00 and gave the company a sell rating in a research report on Wednesday, March 4th. Canaccord Genuity raised their price objective on Crispr Therapeutics from $72.00 to $80.00 and gave the company a positive rating in a research report on Wednesday, November 20th. Needham & Company LLC reissued a buy rating and set a $84.00 price objective on shares of Crispr Therapeutics in a research report on Monday, December 23rd. Finally, Piper Jaffray Companies reissued a buy rating and set a $104.00 price objective on shares of Crispr Therapeutics in a research report on Monday, December 16th.

Large investors have recently modified their holdings of the company. Farmers & Merchants Trust Co of Chambersburg PA bought a new position in shares of Crispr Therapeutics during the fourth quarter valued at $26,000. Webster Bank N. A. bought a new position in shares of Crispr Therapeutics during the fourth quarter valued at $26,000. Advisory Services Network LLC increased its holdings in shares of Crispr Therapeutics by 146.0% during the fourth quarter. Advisory Services Network LLC now owns 674 shares of the companys stock valued at $41,000 after acquiring an additional 400 shares in the last quarter. Clear Harbor Asset Management LLC bought a new position in shares of Crispr Therapeutics during the fourth quarter valued at $44,000. Finally, Exchange Traded Concepts LLC bought a new position in shares of Crispr Therapeutics during the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 52.04% of the companys stock.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.51 EPS for the quarter, beating the consensus estimate of ($0.68) by $1.19. The business had revenue of $77.00 million during the quarter, compared to analyst estimates of $39.08 million. Crispr Therapeutics had a return on equity of 11.74% and a net margin of 23.09%. The companys revenue for the quarter was up 76900.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.92) earnings per share. As a group, equities analysts expect that Crispr Therapeutics will post -4.54 EPS for the current year.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: Do Tariffs Work?

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Read the rest here:
Crispr Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of Buy from Brokerages - Redmond Register

Recommendation and review posted by Bethany Smith